Clinuvel Pharmaceuticals
Melbourne
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing drugs for the treatment of a range of severe skin disorders. Its lead compound, SCENESSE (afamelanotide 16 milligrams), prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company focuses at preventing the symptoms of skin diseases related to the exposure to harmful ultra violet (UV) radiation and at repigmentation of the skin due to a number of depigmentation disorders. SCENESSE has completed Phase II and III trials in the United States and Europe, and has been granted marketing authorization by the European Commission for adults with EPP. It has operations in Europe, the United States and Singapore. SCENESSE acts by increasing the levels of melanin in the skin and shields against UV radiation (UVR) and sunlight. SCENESSE is delivered via a subcutaneous dissolving implant.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Ticker: asx:CUV
- Website: clinuvel.com
- Phone: 61 3 9660 4900
Social Profiles
Canonical: https://fsome.com/organization/clinuvel-pharmaceuticals-2764678 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.